Department of Pharmacognosy, Smriti College of Pharmaceutical Education, Indore, MP, India.
J Ethnopharmacol. 2010 Feb 3;127(2):325-8. doi: 10.1016/j.jep.2009.10.038. Epub 2009 Nov 10.
Paspalum scrobiculatum Linn. (Poaceae) is traditionally used to treat diabetes mellitus. The grains of Paspalum scrobiculatum are having potential in the development of drug for diabetes due to their antidiabetic activity.
To evaluate the antidiabetic activity of aqueous and ethanolic extracts of grains of Paspalum scrobiculatum Linn. (Poaceae) in alloxan induced diabetic rats.
Aqueous and ethanolic extracts (250 and 500 mg/kg body weight), were administered orally to male Wistar albino rats. Alloxan monohydrate was used to induce diabetes mellitus. Total phenolic content was estimated in the extracts. The parameters studied included oral glucose tolerance test, fasting blood glucose, serum insulin and glycated haemoglobin levels, liver glycogen content, serum lipid profile, and changes in body weights.
In oral glucose tolerance test, reduction of fasting blood glucose levels took place from 60 min of extract administration. The extracts produced a dose-dependent fall in fasting blood glucose (FBG). After 15 days of treatment with extracts the maximum reduction in FBG (35.14%) was observed in diabetic rats treated with ethanolic extract 500 mg/kg dose. A significant increase in serum insulin level was observed in the treated rats. Serum lipid levels were reversed towards near normal and a control in the loss of body weight was observed in treated rats as compared to diabetic control. The extract treatment also showed a significant increase in the liver glycogen and a significant decrease in glycated haemoglobin levels. The results demonstrate that Paspalum scrobiculatum possesses significant antidiabetic activity in diabetic rats.
The results suggest that Paspalum scrobiculatum has antidiabetic activity, thereby justifying its traditional claim and augmenting it into the present day systems of medicine.
Paspalum scrobiculatum Linn.（禾本科）传统上用于治疗糖尿病。由于其抗糖尿病活性，Paspalum scrobiculatum 的谷物具有开发糖尿病药物的潜力。
评价 Paspalum scrobiculatum Linn.（禾本科）谷物的水提物和醇提物在链脲佐菌素诱导的糖尿病大鼠中的抗糖尿病活性。
将水提物和醇提物（250 和 500 mg/kg 体重）口服给予雄性 Wistar 白化大鼠。使用一水合链脲佐菌素诱导糖尿病。在提取物中估计总酚含量。研究的参数包括口服葡萄糖耐量试验、空腹血糖、血清胰岛素和糖化血红蛋白水平、肝糖原含量、血清脂质谱以及体重变化。
在口服葡萄糖耐量试验中，从提取物给药后 60 分钟开始降低空腹血糖水平。提取物呈剂量依赖性降低空腹血糖（FBG）。在用提取物治疗 15 天后，用 500mg/kg 剂量的醇提物治疗的糖尿病大鼠中观察到 FBG 的最大降低（35.14%）。治疗大鼠的血清胰岛素水平显著升高。血清脂质水平趋于正常，与糖尿病对照组相比，治疗大鼠的体重减轻得到控制。提取物治疗还显示肝糖原显著增加，糖化血红蛋白水平显著降低。结果表明，Paspalum scrobiculatum 对糖尿病大鼠具有显著的抗糖尿病活性。
结果表明，Paspalum scrobiculatum 具有抗糖尿病活性，从而证明了其传统说法，并将其纳入当今医学体系。
